Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

Trump previously selected Robert Francis Kennedy Jr. to head up the Department of Health and Human Services—the NIH’s parent ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Acadia Pharmaceuticals has penned an exclusive licensing deal worth up to $582 million biobucks for Saniona’s neurological ...

The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an ...